Krystal Biotech的董事会成员在公司强劲但可能估价过高的金融健康条件下从事股票选择活动。 Krystal Biotech's board members engage in stock option activities amid the company’s strong but potentially overvalued financial health.

Krystal Biotech的董事会成员最近积极从事股票选择权交易,有些情况下没有股票交易。 Krystal Biotech's board members have been active in stock option transactions recently, with no shares changing hands in some cases. 该公司以稀有皮肤病基因疗法为重点,显示出强劲的金融健康,总利润率为94.3%,每股正收益,尽管其P/S比率表明估价过高。 The company, focused on gene therapies for rare skin conditions, shows strong financial health with a 94.3% gross margin and positive earnings per share, though its P/S ratio suggests overvaluation. 尽管如此,其较低的P/E和EV/EBITDA比率暗示可能低估估值。 Despite this, its lower P/E and EV/EBITDA ratios hint at potential undervaluation. 投资者应在考虑公司财务指标的同时考虑这些内幕活动。 Investors should consider these insider activities alongside the company's financial metrics.